The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Amsterdam UMC Location University of Amsterdam · Sanquin · +3 more institutions
Abstract
Immune checkpoint inhibitors, including those targeting CTLA-4/B7 and the PD-1/PD-L1 inhibitory pathways, are now available for clinical use in cancer patients, with other interesting checkpoint inhibitors being currently in development. Most of these have the purpose to promote adaptive T cell-mediated immunity against cancer. Here, we review another checkpoint acting to potentiate the activity of innate immune cells towards cancer. This innate immune checkpoint is composed of what has become known as the 'don't-eat me' signal CD47, which is a protein broadly expressed on normal cells and often overexpressed on cancer cells, and its counter-receptor, the myeloid inhibitory immunoreceptor SIRPα. Blocking…
Citation impact
- FWCI
- 16.37
- Percentile
- 100%
- References
- 164
Authors
4- HLHanke L. Matlung
Amsterdam UMC Location University of Amsterdam, Sanquin, University of Amsterdam
- KSKatka Szilagyi
Amsterdam UMC Location University of Amsterdam, Sanquin, University of Amsterdam
- NBNeil Barclay
University of Oxford
- TKTimo K. van den BergCorresponding
Amsterdam UMC Location University of Amsterdam, Sanquin, University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
Topics & keywords
- Immune checkpoint
- Innate immune system
- Cancer
- Biology
- Cancer immunotherapy
- Immune system
- Cancer research
- Cancer cell
- Good health and well-being